Monthly E-News Update
Alzheimer's Association
Having trouble reading this email?
View it in your browser
Forward Forward this message to a Friend
The Alzheimer's Association International Conference® 2018 (AAIC®), the largest international meeting dedicated to advancing dementia science, continues through July 26 in Chicago. As the world's leading forum on dementia research, AAIC® serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. To see media coverage of research presented, please visit our breaking news page. The Association is pleased to present this July report, prepared exclusively for NARFE members, on the latest news in the fight against Alzheimer's. Your continued support is having an impact on the trajectory of this disease.
Senate proposes significant Alzheimer's research funding increase
Senate proposes significant Alzheimer's research funding increase
The Senate Appropriations Labor, Health and Human Services, (Labor-HHS) Education and Related Agencies Subcommittee led by Chairman Roy Blunt (R-Mo.) has answered the call of Alzheimer's advocates by proposing a $425 million increase for Alzheimer's and dementia research funding at the National Institutes of Health (NIH). If signed into law, total funding for the disease at the NIH would reach $2.3 billion. Learn more.
Advocates unite in our nation's capital for 30th Advocacy Forum
Advocates unite in our nation's capital for 30th Advocacy Forum
More than 1,200 energized advocates converged on Washington, D.C., June 17-20 for the 2018 Alzheimer's Association AIM Advocacy Forum. Keynote speaker Dr. Francis Collins, M.D., Ph.D., NIH director, provided an overview of research advancements and encouraged advocates as they prepared for meetings with lawmakers. At the National Alzheimer's Dinner, advocates celebrated victories from the past year and honored outstanding Alzheimer's heroes. Learn more.
Two types of herpesvirus may play role in Alzheimer's
Results of Alzheimer's drug study show promise
This week at AAIC, Eisai Co., Ltd and Biogen Inc. announced additional results of a Phase II clinical trial of a drug called BAN2401. Although the primary results of the study at 12 months were negative in December 2017, researchers reported positive results at 18 months on several secondary outcomes, including reduction of amyloid plaques and improvement of cognition and function. A larger confirmatory trial is needed. Learn more.

Walk with us in the fight against Alzheimer's
Walk with us in the fight against Alzheimer's
Again this year, NARFE is forming a National Walk Team for the Alzheimer's Association Walk to End Alzheimer's®, the world's largest event to raise awareness and funds for Alzheimer's care, support and research. Held in more than 600 communities nationwide, this inspiring event calls on participants of all ages and abilities to join the fight against the disease. Help us reach our national goal of $100,000 while connecting with NARFE members in your community. Register for a NARFE team today.

Online Tools
Alzheimer's Navigator
Caregiver Stress Check
Your Local Community
Find a chapter here
Join Our Mailing List
Sign Up

NARFE Contributions to Advance Alzheimer's Research

NARFE Contributions
Donate Today
24/7 Helpline: 1-800-272-3900
Your donation will strengthen our efforts to advance Alzheimer's care, support and research. From face-to-face support to online education programs and promising global research initiatives, your gift makes a difference in the lives of all those affected by Alzheimer's and other dementias in your community and across the world. Thank you for your continued support.

Alzheimer's Association National Office, 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601
© 2018 Alzheimer's Association. All rights reserved.
800.272.3900 |® | Donate

View your email preferences or unsubscribe.